Head to Head Analysis: Iradimed (NASDAQ:IRMD) versus Endologix (OTCMKTS:ELGXQ)

Endologix (OTCMKTS:ELGXQ) and Iradimed (NASDAQ:IRMD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Endologix and Iradimed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endologix	0	0	0	0	0.00
Iradimed	0	0	3	0	3.00

Iradimed has a consensus price target of $72.00, indicating a potential upside of 38.33%. Given Iradimed’s stronger consensus rating and higher probable upside, analysts clearly believe Iradimed is more favorable than Endologix.

Insider & Institutional Ownership

92.3% of Iradimed shares are held by institutional investors. 1.3% of Endologix shares are held by insiders. Comparatively, 37.1% of Iradimed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Endologix and Iradimed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endologix	N/A	N/A	N/A
Iradimed	26.26%	24.12%	21.20%

Earnings & Valuation

This table compares Endologix and Iradimed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endologix	N/A	N/A	N/A	N/A	N/A
Iradimed	$73.24 million	9.04	$19.23 million	$1.50	34.70

Iradimed has higher revenue and earnings than Endologix.

Summary

Iradimed beats Endologix on 9 of the 9 factors compared between the two stocks.

About Endologix

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. On July 5, 2020, Endologix, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas. It is in joint administration with TriVascular Sales LLC.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.